FOLD Overview
Upcoming Projects (FOLD)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (FOLD)
-
Discussing the FDA Approval of Amicus Therapeutics' Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) combo therapy for treating Pompe Disease.
Ticker: FOLD
Executed On: Oct 27, 2023 at 10:00 AM EDT -
A look at enzyme replacement therapies in Pompe disease including Sanofi's Nexviazyme and Amicus Therapeutics' Pombiliti + Opfolda (AT-GAA)
Tickers: FOLD, SNY
Executed On: Jul 17, 2023 at 05:00 PM EDT -
A review of AT-GAA from Amicus Therapeutics in late-onset Pompe Disease ahead of the PDUFA
Ticker: FOLD
Executed On: Oct 27, 2022 at 06:00 PM EDT -
A Look at Miglustat in Pompe patients after phase 3 PROPEL study results.
Ticker: FOLD
Executed On: Jul 15, 2022 at 10:00 AM EDT
Expired Projects (FOLD)
-
Discussing Amicus’ AT-GAA (cipaglucosidase alfa) for Pompe Disease, following PDUFA Date Extensions
Ticker: FOLD
Execute By: Jun 30, 2022
Upcoming & Overdue Catalysts (FOLD)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (FOLD)
-
Phase 1/2 study testing ATB200 200-02 on Pompe disease data due third quarter of 2017
Ticker: FOLD
Occurred on: Oct 04, 2017 -
NDA filing of Migalastat HCI monotherapy (012) for Fabry Disease delayed following meeting with FDA. Expected to be filed in mid-2016
Ticker: FOLD
Occurred on: Jun 05, 2017 -
Amicus Therapeutics' (FOLD) SD-101 for rare skin blistering disorder earns rare pediatric disease designation from FDA
Ticker: FOLD
Occurred on: May 31, 2017 -
Phase 1/2 additional data for ATB200 in Pompe Disease due at 13th Annual WORLD Symposium February 13-17, 2017.
Ticker: FOLD
Occurred on: Feb 15, 2017 -
Phase 2 interim and final data of ATB200 for Pompe Disease due 2016
Ticker: FOLD
Occurred on: Dec 08, 2016 -
Amicus Therapeutics (FOLD) to complete Phase 3 study of Migalastat (AT1001-041) in patients with Fabry Disease in July 2016
Ticker: FOLD
Occurred on: Aug 10, 2016 -
Amicus (FOLD) to Meet with FDA in Q2 to Discuss Regulatory Path for Migalastat in Treatment of Fabry Disease
Ticker: FOLD
Occurred on: Jun 30, 2016 -
Amicus (FOLD) Expects to Receive EMA Opinion for Migalstat in Fabry Disease at Next CHMP Meeting
Ticker: FOLD
Occurred on: Apr 01, 2016
Strategic Initiatives (FOLD)
-
Amicus Therapeutics (FOLD) and Brammer Bio, a part of Thermo Fisher Scientific (TMO), Enter Strategic Gene Therapy Development and Manufacturing Collaboration
Tickers: FOLD, TMO
Announcement Date: Jul 01, 2019
